Replimune Group (NASDAQ:REPL – Get Rating) had its target price reduced by Piper Sandler to $43.00 in a report released on Monday, Stock Target Advisor reports.
REPL has been the subject of a number of other reports. SVB Leerink reduced their price objective on shares of Replimune Group from $48.00 to $37.00 and set an outperform rating for the company in a research note on Friday, August 5th. HC Wainwright reaffirmed a buy rating and issued a $60.00 target price on shares of Replimune Group in a report on Tuesday, May 24th. Finally, Wedbush lowered their target price on shares of Replimune Group from $59.00 to $52.00 and set an outperform rating on the stock in a report on Tuesday, May 24th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus target price of $45.86.
Get
Replimune Group alerts:
Replimune Group Stock Up 0.2 %
REPL stock opened at $20.68 on Monday. Replimune Group has a 52 week low of $13.05 and a 52 week high of $35.93. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -8.24 and a beta of 1.98. The firm's 50-day moving average is $19.27 and its two-hundred day moving average is $17.40. The company has a current ratio of 19.79, a quick ratio of 19.79 and a debt-to-equity ratio of 0.06.
Replimune Group (NASDAQ:REPL – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.15). On average, analysts forecast that Replimune Group will post -2.99 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Replimune Group
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Amalgamated Bank bought a new position in shares of Replimune Group in the first quarter worth $76,000. Quantbot Technologies LP lifted its stake in Replimune Group by 498.0% in the second quarter. Quantbot Technologies LP now owns 5,980 shares of the company's stock valued at $104,000 after buying an additional 4,980 shares during the period. BNP Paribas Arbitrage SA lifted its stake in Replimune Group by 157.6% in the second quarter. BNP Paribas Arbitrage SA now owns 6,391 shares of the company's stock valued at $112,000 after buying an additional 3,910 shares during the period. Point72 Hong Kong Ltd increased its holdings in shares of Replimune Group by 369.7% during the first quarter. Point72 Hong Kong Ltd now owns 6,919 shares of the company's stock valued at $117,000 after acquiring an additional 5,446 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its holdings in shares of Replimune Group by 25.9% during the second quarter. Virtus ETF Advisers LLC now owns 7,108 shares of the company's stock valued at $124,000 after acquiring an additional 1,461 shares in the last quarter. Institutional investors and hedge funds own 75.42% of the company's stock.
Replimune Group Company Profile
(Get Rating)
Replimune Group, Inc, a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
- Is PayPal A Buy After Post-Earnings Price Jump?
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
